Controversial constitutive TSHR activity: Patients, physiology, and in vitro characterization

Hormone and Metabolic Research

Volumn 46, Issue 7, 2014, Pages 453-461

  Huth, S ^a   Jaeschke, H ^a   Schaarschmidt, J ^a   Paschke, R ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

constitutive activity; hyperthyroidism; TSHR; TSHR mutation

Indexed keywords

ANTITHYROID AGENT; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 4 RECEPTOR; THYROTROPIN RECEPTOR;

DIMERIZATION; GENE MUTATION; HUMAN; HYPERTHYROIDISM; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THYROID CANCER; THYROID GLAND; WILD TYPE; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; THYROID TUMOR;

HUMANS; HYPERTHYROIDISM; MUTATION; PHENOTYPE; RECEPTORS, THYROTROPIN; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 84902551978     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0034-1375651     Document Type: Review

References (71)

1. Costa T., Herz A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA: 1989; 86 7321 7325
2. Kenakin T. The physiological significance of constitutive receptor activity. Editorial, Constitutive Receptor Activity Series. Trends Pharmacol Sci: 2005; 26 603 605
3. Seifert R., Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol: 2002; 366 381 416
4. Milligan G., Bond R. A. Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci: 1997; 18 468 474
5. Milligan G. Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol: 2003; 64 1271 1276
6. Smit M. J., Vischer H. F., Bakker R. A., Jongejan A., Timmerman H., Pardo L., Leurs R. Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. Annu Rev Pharmacol Toxicol: 2007; 47 53 87
7. Milligan G. Novel approaches to enhance the detection of receptor constitutive activity and inverse agonists. International Congress Series: 2003; 1249 15 25
8. Leurs R., Rodriguez Pena M. S., Bakker R. A., Alewijnse A. E., Timmerman H. Constitutive activity of G protein coupled receptors and drug action. Pharm Acta Helv: 2000; 74 327 331
9. Cetani F., Tonacchera M., Vassart G. Differential effects of NaCl concentration on the constitutive activity of the thyrotropin and the luteinizing hormone/chorionic gonadotropin receptors. FEBS Lett: 1996; 378 27 31
10. Dufau M. L. The luteinizing hormone receptor. Annu Rev Physiol: 1998; 60 461 496
11. Simoni M., Gromoll J., Nieschlag E. The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocr Rev: 1997; 18 739 773
12. Mear Y., Enjalbert A., Thirion S. GHS-R1a constitutive activity and its physiological relevance. Front Neurosci: 2013; 7 87
13. Aloyo V. J., Berg K. A., Spampinato U., Clarke W. P., Harvey J. A. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors. Pharmacol Ther: 2009; 121 160 173
14. Srinivasan S., Lubrano-Berthelier C., Govaerts C., Picard F., Santiago P., Conklin B. R., Vaisse C. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J Clin Invest: 2004; 114 1158 1164
15. Galofré J. C., Chacon A. M., Latif R. Targeting thyroid diseases with TSH receptor analogs. Endocrinol Nutr: 2013; 60 590 598
16. Farid N. R., Szkudlinski M. W. Minireview. structural and functional evolution of the thyrotropin receptor. Mol Endocrinol: 2004; 145 4048 4057
17. Lefkowitz R. J., Cotecchia S., Samama P., Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci: 1993; 14 303 307
18. Spiegel A. M. Defects in G protein-coupled signal transduction in human disease. Annu Rev Physiol: 1996; 58 143 170
19. Vassart G., Costagliola S. G protein-coupled receptors: mutations and endocrine diseases. Nat Rev Endocrinol: 2011; 7 362 372
20. Duprez L., Parma J., Van Sande J., Allgeier A., Leclere J., Schvartz C., Delisle M. J., Decoulx M., Orgiazzi J., Dumont J., Vassart G. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet: 1994; 7 396 401
21. Robinson P. R., Cohen G. B., Zhukovsky E. A., Oprian D. D. Constitutively active mutants of rhodopsin. Neuron: 1992; 9 719 725
22. Shenker A., Laue L., Kosugi S., Merendino J. J. Jr, Minegishi T., Cutler G. B. Jr. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature: 1993; 365 652 654
23. de Ligt R. A., Kourounakis A. P., IJzerman A. P. Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol: 2000; 130 1 12
24. Emerson C. H. When will thyrotropin receptor antagonists and inverse thyrotropin receptor agonists become available for clinical use? Thyroid: 2011; 21 817 819
25. Neumann S., Raaka B. M., Gershengorn M. C. Constitutively active thyrotropin and thyrotropin-releasing hormone receptors and their inverse agonists. Methods Enzymol: 2010; 485 147 160
26. Parma J., Duprez L., Van Sande J., Paschke R., Tonacchera M., Dumont J., Vassart G. Constitutively active receptors as a disease-causing mechanism. Mol Cell Endocrinol: 1994; 100 159 162
27. Lüblinghoff J., Nebel I. T., Huth S., Jäschke H., Schaarschmidt J., Eszlinger M., Paschke R. The Leipzig Thyrotropin Receptor Mutation Database: Update 2012. European Thyroid Journal 2012; 1: 209-210.
28. Eszlinger M., Niedziela M., Typlt E., Huth S., Jaeschke H., Schaarschmidt J., Krohn K., Paschke R. Somatic mutations in 29 hot nodules in children. 56 Symposium der Deutschen Gesellschaft für Endokrinologie: 2013; OP: 10-60 (Abstract)
29. Jaeschke H., Mueller S., Eszlinger M., Paschke R. Lack of in vitro constitutive activity for four previously reported TSH receptor mutations identified in patients with nonautoimmune hyperthyroidism and hot thyroid carcinomas. Clin Endocrinol (Oxf): 2010; 73 815 820
30. Niepomniszcze H., Suarez H., Pitoia F., Pignatta A., Danilowicz K., Manavela M., Elsner B., Bruno O. D. Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes. Thyroid: 2006; 16 497 503
31. Tassi V., Di Cerbo A., Porcellini A., Papini E., Cisternino C., Crescenzi A., Scillitani A., Pizzuti A., Ratti A., Trischitta V., Avvedimento V. E., Fenzi G., De F. V. Screening of thyrotropin receptor mutations by fine-needle aspiration biopsy in autonomous functioning thyroid nodules in multinodular goiters. Thyroid: 1999; 9 353 357
32. Mueller S., Gozu H. I., Bircan R., Jaeschke H., Eszlinger M., Lueblinghoff J., Krohn K., Paschke R. Cases of borderline in vitro constitutive thyrotropin receptor activity: how to decide whether a thyrotropin receptor mutation is constitutively active or not? Thyroid: 2009; 19 765 773
33. Neumann S., Krause G., Chey S., Paschke R. A free carboxylate oxygen in the side chain of position 674 in transmembrane domain 7 is necessary for TSH receptor activation. Mol Endocrinol: 2001; 15 1294 1305
34. Schaarschmidt J., Paschke S., Ozerden M., Jaschke H., Huth S., Eszlinger M., Meller J., Paschke R. Late Manifestation of Subclinical Hyperthyroidism After Goitrogenesis in an Index Patient with a N670S TSH Receptor Germline Mutation Masquerading as TSH Receptor Antibody Negative Graves' Disease. Horm Metab Res: 2012; 44 962 965
35. Tonacchera M., Van Sande J., Cetani F., Swillens S., Schvartz C., Winiszewski P., Portmann L., Dumont J. E., Vassart G., Parma J. Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J Clin Endocrinol Metab: 1996; 81 547 554
36. Russo D., Wong M. G., Costante G., Chiefari E., Treseler P. A., Arturi F., Filetti S., Clark O. H. A Val 677 activating mutation of the thyrotropin receptor in a Hurthle cell thyroid carcinoma associated with thyrotoxicosis. Thyroid: 1999; 9 13 17
37. Liu Z., Sun Y., Dong Q., He M., Cheng C. H., Fan F. A novel TSHR gene mutation (Ile691Phe) in a Chinese family causing autosomal dominant non-autoimmune hyperthyroidism. J Hum Genet: 2008; 53 475 478
38. Liu Z., Fan F., Xiao X., Sun Y. Constitutive activation of the thyroid-stimulating hormone receptor (TSHR) by mutating Ile691 in the cytoplasmic tail segment. PLoS One: 2011; 6 e16335
39. Mueller S., Jaeschke H., Paschke R. Current standards, variations, and pitfalls for the determination of constitutive TSHR activity in vitro. Methods Enzymol: 2010; 485 421 436
40. Vlaeminck-Guillem V., Ho S. C., Rodien P., Vassart G., Costagliola S. Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist. Mol Endocrinol: 2002; 16 736 746
41. Berg K. A., Harvey J. A., Spampinato U., Clarke W. P. Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors. Trends Pharmacol Sci: 2005; 26 625 630
42. Gether U., Ballesteros J. A., Seifert R., Sanders-Bush E., Weinstein H., Kobilka B. K. Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem: 1997; 272 2587 2590
43. Herzog H., Hort Y. J., Ball H. J., Hayes G., Shine J., Selbie L. A. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci USA: 1992; 89 5794 5798
44. Kenakin T. Predicting therapeutic value in the lead optimization phase of drug discovery. Nat Rev Drug Discov: 2003; 2 429 438
45. Perez D. M., DeYoung M. B., Graham R. M. Coupling of expressed alpha 1B- and alpha 1D-adrenergic receptor to multiple signaling pathways is both G protein and cell type specific. Mol Pharmacol: 1993; 44 784 795
46. Van Sande J., Swillens S., Gerard C., Allgeier A., Massart C., Vassart G., Dumont J. E. In Chinese hamster ovary K1 cells dog and human thyrotropin receptors activate both the cyclic AMP and the phosphatidylinositol 4,5-bisphosphate cascades in the presence of thyrotropin and the cyclic AMP cascade in its absence. Eur J Biochem: 1995; 229 338 343
47. Grasberger H., Van Sande J., Hag-Dahood M. A., Tenenbaum-Rakover Y., Refetoff S. A familial thyrotropin (TSH) receptor mutation provides in vivo evidence that the inositol phosphates/Ca2+ cascade mediates TSH action on thyroid hormone synthesis. J Clin Endocrinol Metab: 2007; 92 2816 2820
48. Wettschureck N., Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol Rev: 2005; 85 1159 1204
49. Gozu H. I., Mueller S., Bircan R., Krohn K., Ekinci G., Yavuzer D., Sargin H., Sargin M., Ones T., Gezen C., Orbay E., Cirakoglu B., Paschke R. A New Silent Germline Mutation of the TSH Receptor: Coexpression in a Hyperthyroid Family Member with a Second Activating Somatic Mutation. Thyroid: 2008; 18 499 508
50. Gruters A., Schoneberg T., Biebermann H., Krude H., Krohn H. P., Dralle H., Gudermann T. Severe congenital hyperthyroidism caused by a germ-line neo mutation in the extracellular portion of the thyrotropin receptor. J Clin Endocrinol Metab: 1998; 83 1431 1436
51. Nogueira C. R., Kopp P., Arseven O. K., Santos C. L., Jameson J. L., Medeiros-Neto G. Thyrotropin receptor mutations in hyperfunctioning thyroid adenomas from Brazil. Thyroid: 1999; 9 1063 1068
52. Sykiotis G. P., Neumann S., Georgopoulos N. A., Sgourou A., Papachatzopoulou A., Markou K. B., Kyriazopoulou V., Paschke R., Vagenakis A. G., Papavassiliou A. G. Functional significance of the thyrotropin receptor germline polymorphism D727E. Biochem Biophys Res Commun: 2003; 301 1051 1056
53. Sunthornthepvarakul T., Hayashi Y., Refetoff S. Polymorphism of a variant human thyrotropin receptor (hTSHR) gene. Thyroid: 1994; 4 147 149
54. Landis C. A., Masters S. B., Spada A., Pace A. M., Bourne H. R., Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature: 1989; 340 692 696
55. Weinstein L. S., Yu S., Warner D. R., Liu J. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev: 2001; 22 675 705
56. Derwahl M. TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas - a note of caution. J Clin Endocrinol Metab: 1996; 81 2783 2785
57. Trulzsch B., Krohn K., Wonerow P., Chey S., Holzapfel H. P., Ackermann F., Fuhrer D., Paschke R. Detection of thyroid-stimulating hormone receptor and Gsalpha mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis. J Mol Med: 2001; 78 684 691
58. Morshed S. A., Ando T., Latif R., Davies T. F. Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades. Mol Endocrinol: 2010; 151 5537 5549
59. Calebiro D., Nikolaev V. O., Gagliani M. C., de Filippis T., Dees C., Tacchetti C., Persani L., Lohse M. J. Persistent cAMP-signals triggered by internalized G-protein-coupled receptors. PLoS Biol: 2009; 7 e1000172
60. Werthmann R. C., Volpe S., Lohse M. J., Calebiro D. Persistent cAMP signaling by internalized TSH receptors occurs in thyroid but not in HEK293 cells. FASEB J: 2012; 26 2043 2048
61. de Ligt R. A., Kourounakis A. P., IJzerman A. P. Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol: 2000; 130 1 12
62. Smit M. J., Leurs R., Alewijnse A. E., Blauw J., Nieuw Amerongen G. P., Van D. V., Roovers E., Timmerman H. Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors. Proc Natl Acad Sci USA: 1996; 93 6802 6807
63. MacEwan D. J., Milligan G. Up-regulation of a constitutively active form of the beta2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. FEBS Lett: 1996; 399 108 112
64. Fuhrer D., Lewis M. D., Alkhafaji F., Starkey K., Paschke R., Wynford-Thomas D., Eggo M., Ludgate M. Biological activity of activating thyroid-stimulating hormone receptor mutants depends on the cellular context. Mol Endocrinol: 2003; 144 4018 4030
65. van Staveren W. C., Solis D. W., Delys L., Duprez L., Andry G., Franc B., Thomas G., Libert F., Dumont J. E., Detours V., Maenhaut C. Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Res: 2007; 67 8113 8120
66. Bond R. A., IJzerman A. P. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci: 2006; 27 92 96
67. Kursawe R., Paschke R. Modulation of TSHR signaling by posttranslational modifications. Trends Endocrinol Metab: 2007; 18 199 207
68. Leurs R., Smit M. J., Alewijnse A. E., Timmerman H. Agonist-independent regulation of constitutively active G-protein-coupled receptors. Trends Biochem Sci: 1998; 23 418 422
69. Frenzel R., Voigt C., Paschke R. The human thyrotropin receptor is predominantly internalized by beta-arrestin 2. Mol Endocrinol: 2006; 147 3114 3122
70. Neumann S., Geras-Raaka E., Marcus-Samuels B., Gershengorn M. C. Persistent cAMP signaling by thyrotropin (TSH) receptors is not dependent on internalization. FASEB J: 2010; 24 3992 3999
71. Milligan G. The stoichiometry of expression of protein components of the stimulatory adenylyl cyclase cascade and the regulation of information transfer. Cell Signal: 1996; 8 87 95